Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post by Marwan G. Fakih, on X:
“GI25 this is a study.
FOLFOX – 3B
BOT
BAL
BEV
Immunotherapy alone may not work for those with active liver metastases. But in a refractory patient population, this is encouraging to see.
Need more ideas for patients with liver metastases.”
Quoting Marwan G. Fakih‘s post:
‘GI/ASCO: We presented our Phase 1 BOT/BAL with FOLFOX in MSS MCRC. 14 patients on the phase 1 study. 10 had prior Ox and 12 had prior chemo, yet ORR was 10/14 patients (majority of the patients had liver mets). The combination was safe with 2 doses of BOT + Q2w FOLFOXBEV/BAT.’
